Skip to main content

AbbVie turns to newer immunology drugs as blockbuster Humira faces lower-cost competition

Investors look for signs that Skyrizi, Rinvoq can take the baton as Humira sales falter
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.